AlphAIalphai — Financial news for AI agents
accessnewswire.comAUG 271 min read$REGN

REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain officers, alleging securities law violations. The lawsuit covers investors who acquired Regeneron securities between August 1, 2025, and May 15, 2026, claiming misleading statements about a Phase III study.

Original reporting
accessnewswire.com
Published Aug 27, 2026, 6:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 9:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefRegulation
Primary signal
$REGN
Bearish
high confidence
Mentioned
$REGN
Relevance
8/10
alphai data visualization · based on accessnewswire.com
Decision brief

The 30-second read

$REGNBearishHigh
01

Why it matters

The filing adds legal uncertainty and may trigger short‑selling or defensive positioning by investors.

02

Market read

First report of a securities‑fraud suit against a large‑cap biotech; likely to affect REGN's price and sector sentiment.

03

What to watch

Potential settlement terms and the impact of the trial's actual data on valuation.

Relevance 8/10Novelty 8/10Timing: pre-deadline August 2026

Background

Bronstein, Gewirtz & Grossman, a securities‑law firm, announced a class action against Regeneron for alleged misstatements about its Phase III Fianlimab‑Libtayo study.

Company-level read

Ticker impact

$REGNBearishHigh confidence
Context

Regeneron Pharmaceuticals (NASDAQ:REGN) is the target of a newly filed securities fraud class action alleging false statements about its Phase III trial.

Expected impact

potential short-term decline as investors assess exposure

Evidence & confidence

First disclosure of a class action against a large-cap biotech typically triggers sell pressure.

Market effects

Sector

Biotech sector may see heightened scrutiny on trial disclosures.

Regional

U.S. biotech investors could reassess risk exposure.

Global

Limited to firms with similar trial-stage exposures.

Counterpoint

What could challenge this read

If the lawsuit fails, REGN could rebound as the market overreacts.

Key entities

  • company
    Regeneron Pharmaceuticals, Inc.

    Biotech firm targeted by the lawsuit.

  • law_firm
    Bronstein, Gewirtz & Grossman, LLC

    Plaintiff law firm filing the class action.

Read at source← All news

Related articles

AUG 28
$REGNHighAI 9/10

Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline

Regeneron Pharmaceuticals (REGN) faces a securities class action lawsuit after a Phase 3 clinical trial for a melanoma treatment failed, causing a $11B market cap wipeout. The lawsuit alleges Regeneron misled investors about the trial's prospects between August 2025 and May 2026. Investors with losses before the September 2026 deadline are urged to contact Hagens Berman.

prnewswire.com2 min
AUG 27
$REGNMedAI 8/10

Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?

The FDA approved Regeneron's (REGN) Pasatru for fibrodysplasia ossificans progressiva, a rare disease. The drug showed a 94% reduction in new bone lesions in a Phase 3 trial. Regeneron's Q2 revenue was $4.29B, up 17%, with strong sales from Dupixent and Eylea HD. Pasatru's market potential is limited due to the disease's rarity, but it validates Regeneron's research platform.

finance.yahoo.com2 min
AUG 26
$REGNMedAI 8/10

Regeneron terminates mAb eye therapy trial amid safety concerns

Regeneron halted its Phase I/IIa TITAN trial for mAb therapy REGN7041 due to safety concerns, according to a filing and company statement. The trial, targeting noninfectious uveitis, enrolled only one patient. Regeneron cited an unfavorable risk-benefit assessment and noted the cause of the safety event remains unidentified.

bioxconomy.com2 min
AUG 25
$REGNMedAI 9/10

Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline

Regeneron Pharmaceuticals (REGN) faces a securities class action lawsuit over alleged misstatements regarding a Phase 3 clinical trial for a melanoma treatment. The trial's failure caused a $11 billion market cap wipeout, prompting the lawsuit. Investors who purchased shares between August 1, 2025, and May 15, 2026, are urged to contact the law firm Hagens Berman by September 14, 2026.

globenewswire.com3 min
AUG 23
$REGNHighAI 9/10

Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru, a first-in-class treatment for fibrodysplasia ossificans progressiva. The approval is based on positive Phase 3 trial results. Analysts discuss how this new drug may impact Regeneron's investment narrative, alongside existing key products like EYLEA HD and Dupixent. The company projects $19.4B revenue and $6.0B earnings by 2029, with optimistic analysts suggesting higher figures.

simplywall.st2 min
AUG 22
$REGNLow

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regeneron Pharmaceuticals (NASDAQ:REGN) and certain officers, alleging securities law violations. The lawsuit covers investors who acquired Regeneron securities between August 1, 2025, and May 15, 2026, claiming misleading statements about a Phase III study. Investors have until September 14, 2026, to request lead plaintiff status.

accessnewswire.com2 min